President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...

Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...

FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...

Roche is acquiring its cell therapy and genomic medicines partner Poseida Therapeutics, the companies said Tuesday morning.

Aviceda seeks $200M for AVD-104 trial, Nerviano reacquires NMS-293 from Merck KGaA, MaaT Pharma reports positive Phase 1b ALS drug data, Secretome raises $20.4M, 35Pharma secures $35M Series C, ...

The transition team for President-elect Donald Trump was still searching for its next National Institutes of Health director ...

Roche's tiragolumab failed to meet overall survival endpoint in Phase 3 SKYSCRAPER-01 trial when combined with Tecentriq for ...

The Biden ad­min­is­tra­tion pro­posed a new rule Tues­day that would ex­pand Medicare and Med­ic­aid cov­er­age of pop­u­lar ...

Agilent Technologies announced reorganization into three business units: life sciences and diagnostics led by Simon May, ...

Merck is ending Phase 3 trial of Winrevair (sotatercept) early due to positive interim results in treating pulmonary arterial ...